Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast03 in previously treated HER2-positive unresectable or metastatic breast cancer
CTR20190378Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, trastuzumab emtansine in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Nov 2019; status: active.
02
Drugs
trastuzumab deruxtecantrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20190378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190378.